Lactate-rich tumor employs the KAT5–HIF1α axis to modulate the activity of the hypoxia pathway and facilitates tumor progression
Substantial evidence shows that hypoxia-inducible factor 1α (HIF1α) up-regulates glycolytic enzymes and promotes lactate production, which contributes to “Warburg Effect.” Nevertheless, the impact of lactate or lactylation modification on hypoxia signaling pathways within the tumor microenvironment remains largely unclear. Here, we report that lactate can induce the upregulation of hypoxia pathway activity in a HIF1α-dependent manner. We identified that KAT5 as a lysine lactyltransferase of HIF1α and the “writer” responsible for lactylation at HIF1α K389, K460, K674, and K682, and HDAC2 as a HIF1α de-lactylase. The lactylation-deficient mutant of HIF1α (HIF1α 4KR ) reduced HIF1α stability, along with down-regulating hypoxia-mediated angiogenesis, metastasis, apoptosis, and glycolysis. Mechanistically, the HIF1α 4KR mutant enhances the binding of HIF1α to von Hippel-Lindau tumor suppressor protein (VHL), facilitating its degradation. MG149, a KAT5 inhibitor, can enhance the efficacy of anti-programmed cell death protein 1 (PD-1)-based combination immunotherapy in a murine model by suppressing hypoxia pathway activity in tumor cells and potentiating the cytotoxic function of CD8 + T cells. Clinically, lactylated HIF1α and KAT5 are up-regulated in breast cancer tissues compared with adjacent tissues. Notably, elevated levels of HIF1α lactylation and KAT5 expression were observed in resistant cancer specimens from triple-negative breast cancer patients who had undergone neoadjuvant chemoimmunotherapy. Our results indicate that the tumor lactate microenvironment promotes the formation of the tumor hypoxic microenvironment by hijacking and lactylating HIF1α, and the KAT5–HIF1α Kla axis presents a promising therapeutic target for hypoxic tumors.
Authors
- Zhengyan Liang (ORCID: https://orcid.org/0000-0001-7465-0119)
- Yongkang Zou (ORCID: https://orcid.org/0000-0002-0707-7380)
- Zhaoxiang Wang (ORCID: https://orcid.org/0009-0009-3741-768X)
- Zhiguo Wang (ORCID: https://orcid.org/0000-0001-8732-4451)
- Xia Kong (ORCID: https://orcid.org/0009-0007-5555-2557)
- Ying Xue (ORCID: https://orcid.org/0000-0003-4465-3831)
- Yuan Jiao (ORCID: https://orcid.org/0009-0009-1206-1787)
- Junzhi Zhou (ORCID: https://orcid.org/0000-0002-0579-0916)
- Yingzhi Chen
- Zhiwei He
- Weixian Zhou
- Jiayue Wen (ORCID: https://orcid.org/0009-0000-6602-0766)
- Panpan Zhu
- Hewen Ye
Institutions
- Hangzhou Normal University (CN)
- Guangdong Medical College (CN)
- Shenzhen Bay Laboratory (CN)
- Zhongshan People's Hospital (CN)
- Guangdong-Hongkong-Macau Joint Laboratory of Collaborative Innovation for Environmental Quality (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Proceedings of the National Academy of Sciences
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1073/pnas.2627324123
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00